These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37018462)

  • 21. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease.
    Dailey J; Kozhaya L; Dogan M; Hopkins D; Lapin B; Herbst K; Brimacombe M; Grandonico K; Karabacak F; Schreiber J; Liang BT; Salazar JC; Unutmaz D; Hyams JS
    Inflamm Bowel Dis; 2022 Jul; 28(7):1019-1026. PubMed ID: 34528661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
    Woelfel S; Dütschler J; König M; Dulovic A; Graf N; Junker D; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Koller S; Wyss J; Krupka N; Oberholzer M; Frei N; Geissler N; Schaub P; ; Albrich WC; Friedrich M; Schneiderhan-Marra N; Misselwitz B; Korte W; Bürgi JJ; Brand S
    Aliment Pharmacol Ther; 2023 Oct; 58(7):678-691. PubMed ID: 37571863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
    Kennedy NA; Janjua M; Chanchlani N; Lin S; Bewshea C; Nice R; McDonald TJ; Auckland C; Harries LW; Davies M; Michell S; Kok KB; Lamb CA; Smith PJ; Hart AL; Pollok RC; Lees CW; Boyton RJ; Altmann DM; Sebastian S; Powell N; Goodhand JR; Ahmad T
    Gut; 2023 Feb; 72(2):295-305. PubMed ID: 35902214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
    Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
    Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.
    Macaluso FS; Principi M; Facciotti F; Contaldo A; Todeschini A; Saibeni S; Bezzio C; Castiglione F; Nardone OM; Spagnuolo R; Fantini MC; Riguccio G; Caprioli F; Viganò C; Felice C; Fiorino G; Correale C; Bodini G; Milla M; Scardino G; Vernero M; Desideri F; Mannino M; Rizzo G; Orlando A;
    Dig Liver Dis; 2023 Feb; 55(2):154-159. PubMed ID: 36127228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment.
    Pavia G; Spagnuolo R; Quirino A; Marascio N; Giancotti A; Simeone S; Cosco C; Tino E; Carrabetta F; Di Gennaro G; Nobile C; Bianco A; Matera G; Doldo P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.
    Chensue SW; Siler AF; Kim PS; Dimcheff DE; Daghfal DJ; Prostko J; Frias E; Linder KA; Schildhouse RJ
    Microbiol Spectr; 2022 Dec; 10(6):e0274722. PubMed ID: 36409132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
    Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
    J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease.
    Bronsky J; Copova I; Durilova M; Kazeka D; Kubat M; Lerchova T; Vlckova E; Mitrova K; Rataj M; Klocperk A; Sediva A; Hradsky O
    J Pediatr Gastroenterol Nutr; 2023 Feb; 76(2):e36-e44. PubMed ID: 36705698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy.
    Mohamed Mohamed K; Álvarez-Hernández MP; Jiménez García C; Guevara-Hoyer K; Freites D; Martínez Prada C; Pérez-Sancristóbal I; Fernández Gutiérrez B; Mato Chaín G; Rodero M; Rodríguez de la Peña A; Mulero T; Bravo C; Toledano E; Culebras López E; Mediero Valeros B; Pérez Segura P; Sánchez-Ramón S; Candelas Rodríguez G
    Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
    Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.
    Geisen UM; Rose R; Neumann F; Ciripoi M; Vullriede L; Reid HM; Berner DK; Bertoglio F; Hoff P; Hust M; Longardt AC; Lorentz T; Martini GR; Saggau C; Schirmer JH; Schubert M; Sümbül M; Tran F; Voß M; Zeuner R; Morrison PJ; Bacher P; Fickenscher H; Gerdes S; Peipp M; Schreiber S; Krumbholz A; Hoyer BF
    J Med Virol; 2022 Dec; 94(12):5780-5789. PubMed ID: 35945627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
    Wong SY; Wellens J; Helmus D; Marlow L; Brann S; Martinez Pazos V; Weinberg A; Moran HR; McGregor C; Vermeire S; Watanabe K; Kamikozuru K; Ahuja V; Vermani S; Lindsay JO; Kingston A; Dutta U; Kaur H; Silverberg MS; Milgrom R; Chien Ng S; Mak JWY; Cadwell K; Thompson C; Colombel JF; Satsangi J;
    Inflamm Bowel Dis; 2023 Nov; 29(11):1693-1705. PubMed ID: 37354560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
    Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL
    Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
    Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
    Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.